These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28938535)

  • 1. Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test).
    van Agthoven T; Looijenga LHJ
    Oncotarget; 2017 Aug; 8(35):58037-58049. PubMed ID: 28938535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients.
    van Agthoven T; Eijkenboom WMH; Looijenga LHJ
    Cell Oncol (Dordr); 2017 Aug; 40(4):379-388. PubMed ID: 28612337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?
    Radtke A; Cremers JF; Kliesch S; Riek S; Junker K; Mohamed SA; Anheuser P; Belge G; Dieckmann KP
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2383-2392. PubMed ID: 28819887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy.
    Rosas Plaza X; van Agthoven T; Meijer C; van Vugt MATM; de Jong S; Gietema JA; Looijenga LHJ
    Cells; 2019 Oct; 8(10):. PubMed ID: 31597402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical Validation and Performance Characteristics of Molecular Serum Biomarkers, miR-371a-3p and miR-372-3p, for Male Germ Cell Tumors, in a Clinical Laboratory Setting.
    Ye F; Feldman DR; Valentino A; So R; Bromberg M; Khan S; Funt SA; Sheinfeld J; Solit DB; Pessin MS; Peerschke EI
    J Mol Diagn; 2022 Aug; 24(8):867-877. PubMed ID: 35934321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRIPTO and miR-371a-3p Are Serum Biomarkers of Testicular Germ Cell Tumors and Are Detected in Seminal Plasma from Azoospermic Males.
    Spiller CM; Lobo J; Boellaard WPA; Gillis AJM; Bowles J; Looijenga LHJ
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32210110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.
    Dieckmann KP; Radtke A; Spiekermann M; Balks T; Matthies C; Becker P; Ruf C; Oing C; Oechsle K; Bokemeyer C; Hammel J; Melchior S; Wosniok W; Belge G
    Eur Urol; 2017 Feb; 71(2):213-220. PubMed ID: 27495845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor Diagnosis.
    Piao J; Lafin JT; Scarpini CG; Nuño MM; Syring I; Dieckmann KP; Belge G; Ellinger J; Amatruda JF; Bagrodia A; Coleman N; Krailo MD; Frazier AL; Murray MJ
    Clin Genitourin Cancer; 2021 Dec; 19(6):469-479. PubMed ID: 34629299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
    Konneh B; Lafin JT; Howard J; Gerald T; Amini A; Savelyeva A; Woldu SL; Lewis CM; Jia L; Margulis V; Coleman N; Scarpini C; Frazier AL; Murray MJ; Amatruda JF; Bagrodia A
    Andrology; 2023 May; 11(4):634-640. PubMed ID: 36254623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer.
    Lobo J; Leão R; Gillis AJM; van den Berg A; Anson-Cartwright L; Atenafu EG; Kuhathaas K; Chung P; Hansen A; Bedard PL; Jewett MAS; Warde P; O'Malley M; Sweet J; Looijenga LHJ; Hamilton RJ
    Eur Urol Oncol; 2021 Jun; 4(3):483-491. PubMed ID: 33288479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
    Badia RR; Abe D; Wong D; Singla N; Savelyeva A; Chertack N; Woldu SL; Lotan Y; Mauck R; Ouyang D; Meng X; Lewis CM; Majmudar K; Jia L; Kapur P; Xu L; Frazier AL; Margulis V; Strand DW; Coleman N; Murray MJ; Amatruda JF; Lafin JT; Bagrodia A
    J Urol; 2021 Jan; 205(1):137-144. PubMed ID: 32856980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular origin of microRNA-371a-3p in healthy males based on systematic urogenital tract tissue evaluation.
    Boellaard WPA; Gillis AJM; van Leenders GJLH; Stoop H; van Agthoven T; Dorssers LCJ; Dinkelman-Smit M; Boormans JL; Looijenga LHJ
    Andrology; 2019 Jul; 7(4):463-468. PubMed ID: 30786164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refining the serum miR-371a-3p test for viable germ cell tumor detection.
    Lafin JT; Scarpini CG; Amini A; Konneh B; Howard JM; Gerald T; Nuno M; Piao J; Savelyeva A; Wang Z; Gagan J; Jia L; Lewis CM; Murray S; Sawa YC; Margulis V; Woldu SL; Strand DW; Coleman N; Amatruda JF; Frazier AL; Murray MJ; Bagrodia A
    Sci Rep; 2023 Jun; 13(1):10558. PubMed ID: 37386046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
    Spiekermann M; Belge G; Winter N; Ikogho R; Balks T; Bullerdiek J; Dieckmann KP
    Andrology; 2015 Jan; 3(1):78-84. PubMed ID: 25187505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
    Christiansen AJ; Lobo J; Fankhauser CD; Rothermundt C; Cathomas R; Batavia AA; Grogg JB; Templeton AJ; Hirschi-Blickenstorfer A; Lorch A; Gillessen S; Moch H; Beyer J; Hermanns T
    Front Oncol; 2022; 12():1056823. PubMed ID: 36568207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graded expression of microRNA-371a-3p in tumor tissues, contralateral testes, and in serum of patients with testicular germ cell tumor.
    Belge G; Hennig F; Dumlupinar C; Grobelny F; Junker K; Radtke A; Dieckmann KP
    Oncotarget; 2020 Apr; 11(16):1462-1473. PubMed ID: 32363003
    [No Abstract]   [Full Text] [Related]  

  • 17. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.
    Syring I; Bartels J; Holdenrieder S; Kristiansen G; Müller SC; Ellinger J
    J Urol; 2015 Jan; 193(1):331-7. PubMed ID: 25046619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of microRNA-371a-3p and 375-5p can distinguish viable germ cell tumor and teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens.
    Kremer L; von Brandenstein M; Wittersheim M; Koeditz B; Paffenholz P; Hellmich M; Pfister D; Heidenreich A; Nestler T
    Transl Androl Urol; 2021 Apr; 10(4):1647-1655. PubMed ID: 33968653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
    Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
    J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range.
    Lafin J; Scarpini C; Amini A; Konneh B; Howard J; Gerald T; Nuno M; Piao J; Savelyeva A; Wang Z; Gagan J; Jia L; Lewis C; Murray S; Sawa Y; Margulis V; Woldu S; Strand D; Coleman N; Amatruda J; Frazier L; Murray M; Bagrodia A
    Res Sq; 2023 Mar; ():. PubMed ID: 36993198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.